Try our Advanced Search for more refined results
Health - May, 2004
27 articles
- Appeals Court Bars Andrx From Using "Altotocor" Brand Name
- Andrx Relinquishes Exclusivity Rights To 150mg Generic Zyban
- FTC OKs Bristol-Myers/Teva Deal On Paraplatin
- NIH Hears Arguments Over Compulsory License For AIDS Drug
- Altana Files Patent Suit Vs. Teva Over Anti-Ulcer Drug
- GlaxoSmithKline To Pay $75M To Settle Patent Suit
- Medtronic Units Infringed Interpore Cross Patent, Court Finds
- U.S. District Court Judge Issues Permanent Injunction Vs. Ventana
- Teva To Continue Selling Generic Vicoprofen After Losing Vs. Abbott At Federal Circuit
- EPO Revokes Controversial Patent For Breast Cancer Screening
- NYC Files Antitrust Suit Vs. Glaxo Over Paxil Patents
- Court Rejects Motion To Declare Roche DNA Replication Technology Patents Unenforceable
- Purdue To Hold Off On Oxycontin Generics Until Federal Circuit Ruling
- Court Strips B. Braun Of Key Patent In Dispute With Inventor
- Canada Passes Law Authorizing Generic Drug Exports
- Abbott Faces Calls For Compulsory License For Norvis
- Canada To Pass Generics Bill Friday
- Federal Circuit Rules For Elan In Naproxen Patent Suit
- Cephalon Plans To File Patent Suit Vs Sandoz Over Provigil ANDA
- Global Generic Drug Market To Grow 10%-15% Annually, Survey Says
- PhRMA Urges FDA To Flesh Out Medicare Act Provisions On 180-Day Exclusivity
- Canada Set To OK Patent Law Amendments This Week
- Pfizer Sues Websites for Selling Illegal Lipitor Generic
- Repligen, MIT Sue ImClone Over Erbitux Patent
- Poverty, Not Patents, Greatest Barrier To Drug Access For Poor, Study Finds
- Genentech Asks FDA TO Hold Off Biogenerics Policy Paper
- Judge Denies Request To Dismiss Patent Challenge Vs. Glaxo's AZT